Febrile Neutropenia Epidemiology Forecast
Febrile Neutropenia Insights and Trends
- Febrile neutropenia shows a higher incidence rate in hematological malignancies than in solid tumors; however, the overall number of cases of febrile neutropenia is greater in solid tumors due to their higher patient population.
- The total chemotherapy usage per year in the 7MM was 1,906,000 of which the United States accounted for the largest share; ~36% in 2025. Chemotherapy usage is expected to rise significantly in the coming years due to the increase in cancer incidence, expanding access to oncology care, increased patient demand and broader adoption of chemo in combination with other therapies.
- Chemotherapy-induced neutropenia (CIN) and febrile neutropenia are common and potentially life-threatening complications of myelotoxic chemotherapy, particularly with regimens carrying a high risk or an intermediate risk in patients with additional risk factors.
- Febrile neutropenia remains a major driver of cancer treatment-related complications, significantly increasing the risk of infections, hospitalizations, treatment delays, and mortality.
- In the US, the comorbidity-specific rate of febrile neutropenia is highest among patients with cardiovascular disease, followed by those with allergies and lung disease, indicating a greater burden in cardiovascular comorbid conditions.
- Febrile neutropenia patients are predominantly in the intermediate-risk category, followed by a considerably low-risk group, with only a small proportion classified as high-risk, reflecting an overall moderate-risk predominance.
Febrile Neutropenia Epidemiology forecast
- 2025 Incident Cases of Febrile Neutropenia: ~ 547,500
- Febrile neutropenia Growth Rate (2026–2036): 1.5% CAGR
DelveInsight's ‘Febrile Neutropenia – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Febrile neutropenia, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2026 |
|
Geographies Covered |
|
|
Febrile neutropenia Epidemiology CAGR (Study period/Forecast period) |
1.5% (2026–2036) |
|
Febrile neutropenia Epidemiology Segmentation Analysis |
Patient Burden Assessment
|
Febrile Neutropenia Understanding and Treatment Algorithm
Febrile Neutropenia Overview and Diagnosis
Despite advances in oncology, Febrile Neutropenia remains a significant clinical challenge, associated with high morbidity, mortality, and healthcare costs due to infectious complications driven by impaired immunity and evolving antimicrobial resistance; this underscores the critical need for rapid pathogen identification, timely empiric broad-spectrum therapy, and optimized treatment strategies supported by emerging diagnostics and antimicrobial stewardship approaches.
Effective management of Febrile Neutropenia requires a comprehensive and timely diagnostic approach, beginning with evaluation of prior and latent infections and thorough clinical assessment of common infection sites such as the lungs, skin, mucosa, catheter sites, and major organ systems. Risk stratification tools like PEN-FAST can help guide safe antibiotic selection in patients with reported penicillin allergy. At onset, prompt work-up including clinical examination, blood cultures, laboratory testing, and symptom-directed imaging is essential, with cultures ideally obtained before initiating antibiotics. While advanced diagnostics such as PCR and biomarkers like procalcitonin can aid in pathogen detection, they complement rather than replace standard methods. Imaging, particularly CT scans, should be guided by clinical presentation, as routine chest X-rays have limited sensitivity. In high-risk patients, additional targeted screening for fungal infections and selective use of invasive diagnostics can further support optimal management.
Further details are provided in the report.
Febrile Neutropenia Epidemiology
Key Findings from Febrile Neutropenia Epidemiological Analysis and Forecast
- In 2025, chemotherapy-associated cases accounted for 692,000 and this number is projected to increase to 841,500 by 2036, growing at a CAGR of 1.8%.
- Among the EU4 countries and the UK, Germany recorded the highest number of incident cases in 2025, accounting for ~24% of the total incident cases across these regions.
- The incidence of febrile neutropenia shows a higher trend among males compared to females, suggesting a relatively greater susceptibility in male patients.
- Febrile neutropenia patients are predominantly in the intermediate-risk category, followed by a considerably low-risk group, with only a small proportion classified as high-risk, reflecting an overall moderate-risk predominance.
Scope of the Report
- The report covers a segment of a descriptive overview of Febrile neutropenia, explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- Febrile neutropenia Patient population forecast
Report Key Strengths
- Epidemiology-based (Epi-based) bottom-up forecasting
- 11-year forecast
- Patient Burden trends (by geography)
FAQs
- What are the disease risks, burdens, and unmet needs of Febrile neutropenia? What will be the growth opportunities across the 7MM concerning the patient population with Febrile neutropenia?
- What is the historical and forecasted Febrile neutropenia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
